C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
5 September 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today provides an update on the Drug Discovery Engine and portfolio progress.
The company has continued to make progress towards its aim of becoming the world’s most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas.
Key drug discovery programmes in addiction and inflammation have advanced and our Taxonomy3® DNA-based target discovery technology is producing novel target data in a number of commercially valuable disease areas. These targets can be addressed through our drug design platform including our Conformetrix and Molplex chemistry technologies and we are in discussions with a number of potential pharmaceutical partners which we anticipate will result in a deal in line with our previously announced expectations.
Dr Clive Dix, CEO of C4X Discovery, said: “We continue to develop the data package around our most advanced drug candidate, an Orexin-1 antagonist aimed at treating addiction, and have recently completed a study in cocaine-induced brain dopamine elevation. Combined with our already compelling pre-clinical data package around nicotine addiction, we are confident that our lead programme represents a highly attractive prospect for partnering with pharma and the initial discussions are progressing as we had hoped.
“We are also increasingly seeing the power of our drug discovery engine with exciting new targets identified in inflammation and neurodegenerative diseases. These open new opportunities to develop valuable new discovery programmes and early-stage revenue-generating deals with the pharmaceutical industry.”